Please assess the completion status of the following clinical trial:

Trial Title: Yttrium Y 90 Anti-CD19 Antibody BU-12 in Patients With Advanced Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed CD19-positive (\> 25% by flow cytometry evaluation of bone marrow blasts) disease of 1 of the following types:~  * Primary refractory or relapsed acute lymphoblastic leukemia (ALL) defined as persistent disease following a minimum of two different standard effective chemotherapy induction attempts at time of diagnosis or at relapse~ * Chronic Lymphocytic leukemia (CLL) following blast crisis (≥15% bone marrow blasts following a minimum of one standard effective chemotherapy induction attempt)~* Human anti-mouse antibody (HAMA) must be negative~* Patients who have relapsed ≥ 60 days following an autologous or allogeneic transplant are eligible if all other eligibility criteria are met~* No active central nervous system (CNS) disease~* ECOG performance status (PS) 0-2 or Karnofsky PS 60-100%~* Life expectancy \> 8 weeks~* Total bilirubin ≤ 2.5 times upper limit of normal (ULN)~* AST and ALT ≤ 2.5 times ULN~* Creatinine normal OR creatinine clearance ≥ 60 mL/min~* LVEF ≥ 45% by MUGA/ECHO~* Oxygen saturation on room air \> 92% and no oxygen requirement~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients mus use effective contraception~Exclusion criteria:~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to of yttrium Y 90 anti-CD19 antibody BU-12 or other agents used in study~* Uncontrolled illness including, but not limited to, any of the following:~  * Ongoing or active infection~ * Symptomatic congestive heart failure~ * Unstable angina pectoris~ * Cardiac arrhythmia~ * Psychiatric illness/social situations that would limit compliance with study requirements~* HIV-positive~* Active graft-vs-host disease~* Less than 4 weeks since prior agents and recovered~* Less than 7 days since prior therapy with any biologic agent, defined as a growth factor or cytokine~* Less than 3 months since prior antibody or biologic anticancer therapy (e.g., alemtuzumab or epratuzumab)~* Other concurrent investigational agents~* Patients with peripheral blasts \> 5,000/uL may receive concurrent hydroxyurea

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 111 In-BU-12 (Type: EXPERIMENTAL): 111In-BU-12 is the 111Indium-labeled murine monoclonal antibody used for imaging and dosimetry.

Based on this trial design, predict the completion outcome and termination type (if applicable).